Open Payments

Mary Imogene Bassett Hospital

Type
Teaching hospital
Where
Cooperstown, NY
Medicare CCN
330136
Received
$91,275 in 20 records, 2025 ($1,958 general, $89,316 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment6$1,958
2025Research payment14$89,316

By company

CompanyRecordsAmountYears
Genentech, Inc.1$68,3342025
AstraZeneca Pharmaceuticals LP1$6,9002025
Novartis Pharmaceuticals Corporation5$6,3722025
Novocure Inc.3$6,1112025
Aesculap Implant Systems, LLC1$1,0152025
PFIZER INC.3$9422025
Abbott Laboratories3$7912025
E.R. Squibb & Sons, L.L.C.1$6562025
Stryker Corporation2$1512025

By nature of payment

NatureRecordsAmount
Research payment14$89,316
Debt forgiveness2$1,051
Space rental or facility fees (teaching hospital only)3$791
Long term medical supply or device loan1$116

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$116Long term medical supply or device loanIn-kind items and servicesOVERBED TABLE TRU-FIT Device, FURNITURE2025
2025-12-31Novartis Pharmaceuticals Corporation$57Research paymentIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular DiseasesRandomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-12-31Stryker Corporation$35Debt forgivenessCash or cash equivalent2025
2025-12-17Aesculap Implant Systems, LLC$1,015Debt forgivenessCash or cash equivalent2025
2025-11-20Abbott Laboratories$467Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-05AstraZeneca Pharmaceuticals LP$6,900Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismDapagliflozin in Acute Decompensated Heart Failure2025
2025-10-27Novartis Pharmaceuticals Corporation$348Research paymentIn-kind items and servicesA Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participa2025
2025-09-15Novartis Pharmaceuticals Corporation$5,006Research paymentCash or cash equivalentA Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participa2025
2025-08-19Novartis Pharmaceuticals Corporation$900Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-07-11E.R. Squibb & Sons, L.L.C.$656Research paymentCash or cash equivalentCAMZYOS Drug, CardiovascularA Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes2025
2025-07-11PFIZER INC.$34Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-05-01Novocure Inc.$2,500Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2025
2025-04-10Abbott Laboratories$297Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-04-10Abbott Laboratories$27Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-04-01PFIZER INC.$66Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-03-31Novartis Pharmaceuticals Corporation$59Research paymentIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular DiseasesRandomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-03-25Genentech, Inc.$68,334Research paymentCash or cash equivalentXofluza Drug, Virology & Specialty CareThe COMBO 1 Trial2025
2025-01-09Novocure Inc.$3,066Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2025
2025-01-09PFIZER INC.$841Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-01-09Novocure Inc.$544Research paymentCash or cash equivalentEF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New York; placed by its state only.

MeasureState
New York
Population B0100319,852,366
Population, 2020 census P120,201,249
Median age B0100239.8
Under 18 B0100120.5%
65 and over B0100117.9%
Households B110017,722,646
Foreign born B0500222.8%
Median household income B19013$85,974
Median family income B19113$106,873
Per capita income B19301$50,712
Poverty rate B1700114.0%
Unemployment rate B230256.4%
Civilian labor force B2302510,171,766
Mean commute (minutes) B0801332.6
Bachelor's degree or higher B1500340.2%
Housing units B250018,585,241
Owner-occupied B2500354.3%
Renters B2500345.7%
Median home value B25077$423,800
Median gross rent B25064$1,621
White, not Hispanic B0300252.8%
Black B0300213.4%
Hispanic or Latino B0300219.8%
Asian B030029.0%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.